Valproic Acid Antagonizes the Capacity of Other Histone Deacetylase Inhibitors To Activate the Epstein-Barr Virus Lytic Cycle
- 1 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (11) , 5628-5643
Abstract
Diverse stimuli reactivate the Epstein-Barr virus (EBV) lytic cycle in Burkitt lymphoma (BL) cells. In HH514-16 BL cells, two histone deacetylase (HDAC) inhibitors, sodium butyrate (NaB) and trichostatin A (TSA), and the DNA methyltransferase inhibitor azacytidine (AzaCdR) promote lytic reactivation. Valproic acid (VPA), which, like NaB, belongs to the short-chain fatty acid class of HDAC inhibitors, fails to induce the EBV lytic cycle in these cells. Nonetheless, VPA behaves as an HDAC inhibitor; it causes hyperacetylation of histone H3 (J. K. Countryman, L. Gradoville, and G. Miller, J. Virol.82:4706–4719, 2008). Here we show that VPA blocked the induction of EBV early lytic proteins ZEBRA and EA-D in response to NaB, TSA, or AzaCdR. The block in lytic activation occurred prior to the accumulation of BZLF1 transcripts. Reactivation of EBV in Akata cells, in response to anti-IgG, and in Raji cells, in response to tetradecanoyl phorbol acetate (TPA), was also inhibited by VPA. MS-275 and apicidin, representing two additional classes of HDAC inhibitors, and suberoylanilide hydroxamic acid (SAHA) reactivated EBV in HH514-16 cells; this activity was also inhibited by VPA. Although VPA potently blocked the expression of viral lytic-cycle transcripts, it did not generally block the transcription of cellular genes and was not toxic. The levels and kinetics of specific cellular transcripts, such as Stat3, Frmd6, Mad1, Sepp1, c-fos, c-jun, andegr1, which were activated by NaB and TSA, were similar in HH514-16 cells treated with VPA. When combined with NaB or TSA, VPA did not inhibit the activation of these cellular genes. Changes in cellular gene expression in response to VPA, NaB, or TSA were globally similar as assessed by human genome arrays; however, VPA selectively stimulated the expression of some cellular genes, such as MEF2D, YY1, and ZEB1, that could repress the EBV lytic cycle. We describe a novel example of functional antagonism between HDAC inhibitors.Keywords
This publication has 108 references indexed in Scilit:
- Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic AcidClinical Infectious Diseases, 2009
- Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumorsNature Medicine, 2008
- Chromatin organization and virus gene expressionJournal of Cellular Physiology, 2008
- Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasionProceedings of the National Academy of Sciences, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 2004
- Virally targeted therapies for EBV-associated malignanciesOncogene, 2003
- Anti‐tumor mechanisms of valproate: A novel role for an old drugMedicinal Research Reviews, 2002